Challenges in the Development of Novel Cardiovascular Therapies: New Target for Lowering LDL: PCSK-9

More Information

What kind of information would you like to request?     More Information       Make a Referral

Leave this field empty

Chief Medical Officer of Amgen, Paul Eisenberg, MD, discusses the insights he has learned working on drug development, specifically the cardiovacscular drug that lowers LDL, PCSK-9.

Paul Eisenberg, MD
Senior Vice President, Global Medical and Chief Medical Officer
Amgen

Comments